Genmab

$35.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.68 (+1.93%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Genmab and other stocks, options, and ETFs commission-free!

About GMAB

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark. The listed name for GMAB is Genmab A/S ADS.

CEO
Jan G. J. van de Winkel
Employees
548
Headquarters
Copenhagen, Capital Region
Founded
1999
Market Cap
23.49B
Price-Earnings Ratio
27.86
Dividend Yield
Average Volume
503.43K
High Today
$36.19
Low Today
$35.71
Open Price
$35.72
Volume
251.05K
52 Week High
$39.81
52 Week Low
$16.24

Collections

GMAB Earnings

$0.00
$2.53
$5.05
$7.58
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Available Feb 23

You May Also Like